SOCM
CRSP icon

SR One Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

SR One Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Hold
2,038,763
– – 10.7% 3
2026
Q1 		$97M Hold
2,038,763
– – 10.59% 4
2025
Q4 		$107M Hold
2,038,763
– – 15.14% 3
2025
Q3 		$132M Buy
2,038,763
+989,812
+94% +$56.8M 19.11% 2
2025
Q2 		$51M Hold
1,048,951
– – 11.06% 3
2025
Q1 		$35.7M Hold
1,048,951
– – 9.17% 5
2024
Q4 		$41.3M Hold
1,048,951
– – 10.07% 3
2024
Q3 		$49.3M Hold
1,048,951
– – 9.88% 4
2024
Q2 		$56.7M Hold
1,048,951
– – 17.74% 2
2024
Q1 		$71.5M Buy
+1,048,951
New +$75.1M 19.64% 2

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SR One Capital Management's CRSP Position: Q2 2026 in Review

SR One Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 2,038,763 shares worth $111M. The position accounts for 10.7% of the portfolio, ranked #3.

SR One Capital Management first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $132M in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SR One Capital Management held 2,038,763 shares of CRISPR Therapeutics worth $111M as of Q2 2026.
  • SR One Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 10.7% of SR One Capital Management's portfolio in Q2 2026, its #3 holding.
  • SR One Capital Management first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • SR One Capital Management's CRISPR Therapeutics position peaked at $132M in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.